Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily due to decreases in clinical trial costs ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinica ...